Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Ms. Eastland is an accomplished biopharmaceutical executive with substantial leadership experience operating late-stage oncology companies. She previously served as Chief Executive Officer at Harpoon ...

Is your lab prepared for the growing demands of PFAS testing as regulations tighten? With contamination risks high, accuracy ...

On the other hand, Merck Foundation is also partnering the donation under its ... we can give to them to become great adults in future,” Madam Sakyi said. Ms Djaba, on her part, lauded both ...

We are raising our fair value estimate for Waters to $340 per share, from $323 previously, based on cash flows generated since our last valuation update. Our valuation is based on discounted cash ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling the end of the programme ...

German science and technology company Merck lowered mid-term targets for its Life Sciences and Healthcare businesses, anticipating an update on China's growth prospects and following a string of ...

The US approval for relapsing/remitting and secondary progressive MS comes a couple of years after Merck won European approval for Mavenclad (cladribine), and several years after the first ...

Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has expanded its leadership team with the appointments of Jan ...

Ms. Hood holds a BSC Hons in Biochemistry from the University ... In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify ...